A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, Klara; Chernova, Julia; Hastings, Margaret; Lam, Ching; Marciani, Luca; Singh, Gulzar; Henry, Amanda P.; Hall, Ian P.; Whorwell, Peter; Spiller, Robin C.
LUCA MARCIANI LUCA.MARCIANI@NOTTINGHAM.AC.UK
Professor of Gastrointestinal Imaging
GULZAR SINGH GULZAR.SINGH@NOTTINGHAM.AC.UK
Amanda P. Henry
Ian P. Hall
Robin C. Spiller
Background: Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness in IBS-D.
Methods: 120 patients meeting Rome III criteria for IBS-D entered a randomised, double-blind, placebo-controlled crossover study of 5 weeks of ondansetron 4 mg versus placebo with dose titration allowed, up to two tablets three times daily in the first 3 weeks. Patients completed daily diaries documenting stool consistency using the Bristol Stool Form score. Gut transit was measured in the last week of each treatment. The primary endpoint was average stool consistency in the last 2 weeks of treatment.
Results: Ondansetron significantly improved stool consistency (mean difference in stool form between ondansetron and placebo −0.9, 95% CI −1.1 to −0.6, p less than 0.001). Compared with placebo, patients on ondansetron experienced fewer days with urgency (p
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., …Spiller, R. C. (2014). A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut, 63(10), 1617-1625. https://doi.org/10.1136/gutjnl-2013-305989
|Journal Article Type||Article|
|Acceptance Date||Nov 17, 2013|
|Online Publication Date||Dec 12, 2013|
|Deposit Date||May 8, 2014|
|Publicly Available Date||May 8, 2014|
|Publisher||BMJ Publishing Group|
|Peer Reviewed||Peer Reviewed|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0|
Publisher Licence URL
You might also like
Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia